Pliant Therapeutics stock tumbles amid IPF trial cancellation
The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.
Pliant Therapeutics reinstated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald reinstated coverage of Pliant Therapeutics (PLRX) with a Neutral rating and no price target The company is discontinuing the ...